Anti-Human HLA-DRB1 Reference Antibody (Apolizumab, RUO) (HF974016)

Name: Anti-Human HLA-DRB1 Reference Antibody (Apolizumab, RUO)
Brand: abinScience
SKU: HF974016
Price: 176 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HF974016
Descripción	Apolizumab (HF974016) is a research-grade recombinant antibody targeting HLA class II histocompatibility antigen. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Reactividad de especies	Human
Aplicaciones	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	IgG1-nd
Sistema de expresión	Mammalian cells
Objetivo	HLA class II histocompatibility antigen, DRB1 beta chain, Human leukocyte antigen DRB1, HLA-DRB1
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% purity as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	P01911
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4 Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Nombres alternativos	Hu1D10, 267227-08-7
Fondo	HLA class II histocompatibility antigen, DRB1 beta chain (HLA-DRB1) is a ~29 kDa protein. A beta chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the alpha chain HLA-DRA, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DRB1-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells. Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes. In the tumor microenvironment, presents antigenic peptides that are primarily generated in tumor-resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins. 1. Shams, H. et al. (2004) Journal of immunology (Baltimore, Md. : 1950) 173, 1966-77. PMID: 15265931 2. Schulze zur Wiesch, J. et al. (2005) Journal of immunology (Baltimore, Md. : 1950) 175, 3603-13. PMID: 16148104 3. Kwok, WW. et al. (2012) Journal of immunology (Baltimore, Md. : 1950) 188, 2537-44. PMID: 22327072 4. Muehling, LM. et al. (2016) Journal of immunology (Baltimore, Md. : 1950) 197, 3214-3224. PMID: 27591323 5. Galperin, M. et al. (2018) Science immunology 3. PMID: 29884618 6. Abelin, JG. et al. (2019) Immunity 51, 766-779.e17. PMID: 31495665 7. Topalian, SL. et al. (1996) The Journal of experimental medicine 183, 1965-71. PMID: 8642306 8. Stern, LJ. et al. (1994) Nature 368, 215-21. PMID: 8145819 9. Schmid, D. et al. (2007) Immunity 26, 79-92. PMID: 17182262
Nota	For research use only. Not suitable for clinical or therapeutic use.
Isotype Control	Human IgG1 (LALAPG) Recombinant Isotype Control Antibody (HyHEL-10) (HP688307) Human IgG1 (LALA) Recombinant Isotype Control Antibody (HyHEL-10) (HP688107)